Berkshire Bank Lowers Stake in Eli Lilly and Company (NYSE:LLY)

Berkshire Bank lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,629 shares of the company’s stock after selling 100 shares during the quarter. Berkshire Bank’s holdings in Eli Lilly and Company were worth $1,702,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in LLY. Silicon Valley Capital Partners purchased a new position in shares of Eli Lilly and Company in the first quarter worth $25,000. Bogart Wealth LLC lifted its holdings in shares of Eli Lilly and Company by 193.3% in the first quarter. Bogart Wealth LLC now owns 88 shares of the company’s stock worth $30,000 after buying an additional 58 shares in the last quarter. Laffer Tengler Investments purchased a new position in shares of Eli Lilly and Company in the first quarter worth $33,000. Raleigh Capital Management Inc. lifted its holdings in shares of Eli Lilly and Company by 156.4% in the first quarter. Raleigh Capital Management Inc. now owns 100 shares of the company’s stock worth $34,000 after buying an additional 61 shares in the last quarter. Finally, Tanglewood Legacy Advisors LLC purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth $37,000. Hedge funds and other institutional investors own 81.38% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 37,660 shares of the firm’s stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $546,751.75, for a total transaction of $20,590,670,905.00. Following the transaction, the insider now owns 100,275,279 shares of the company’s stock, valued at approximately $54,825,684,274,988.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Alonzo Weems sold 1,148 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total value of $678,445.04. Following the sale, the executive vice president now directly owns 7,760 shares in the company, valued at approximately $4,586,004.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 37,660 shares of the firm’s stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $546,751.75, for a total transaction of $20,590,670,905.00. Following the completion of the sale, the insider now owns 100,275,279 shares in the company, valued at $54,825,684,274,988.30. The disclosure for this sale can be found here. In the last quarter, insiders have sold 976,153 shares of company stock valued at $21,080,192,113. Company insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

LLY has been the topic of several research analyst reports. Argus boosted their target price on shares of Eli Lilly and Company from $470.00 to $620.00 and gave the stock a “buy” rating in a report on Tuesday, September 5th. Barclays upped their price target on shares of Eli Lilly and Company from $500.00 to $590.00 and gave the company an “overweight” rating in a research note on Wednesday, August 9th. UBS Group upped their price target on shares of Eli Lilly and Company from $447.00 to $498.00 and gave the company a “buy” rating in a research note on Wednesday, May 24th. Truist Financial upped their price target on shares of Eli Lilly and Company from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Wednesday, August 9th. Finally, BMO Capital Markets upped their price target on shares of Eli Lilly and Company from $565.00 to $633.00 and gave the company an “outperform” rating in a research note on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and twenty have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $532.78.

Eli Lilly and Company Trading Down 0.8 %

NYSE LLY opened at $571.17 on Tuesday. The company’s 50-day moving average price is $512.56 and its 200-day moving average price is $439.28. The company has a current ratio of 1.13, a quick ratio of 0.87 and a debt-to-equity ratio of 1.63. The stock has a market cap of $542.21 billion, a PE ratio of 79.44, a PEG ratio of 2.37 and a beta of 0.32. Eli Lilly and Company has a 12 month low of $296.32 and a 12 month high of $601.84.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, August 8th. The company reported $2.11 EPS for the quarter, beating analysts’ consensus estimates of $1.98 by $0.13. The business had revenue of $8.31 billion for the quarter, compared to the consensus estimate of $7.58 billion. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The company’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter last year, the firm posted $1.25 EPS. Equities research analysts forecast that Eli Lilly and Company will post 9.84 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th were given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date was Monday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 62.87%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.